Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Study of Docetaxel Plus Carboplatin in Patients With Hormone Refractory Prostate Cancer

This study has been completed.
Bristol-Myers Squibb
Beth Israel Deaconess Medical Center
Lowell General Hospital
Massachusetts General Hospital
Oregon Health and Science University
Wentworth-Douglass Hospital
Information provided by:
Dana-Farber Cancer Institute Identifier:
First received: August 24, 2005
Last updated: December 7, 2009
Last verified: December 2009
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: September 2009
  Primary Completion Date: April 2006 (Final data collection date for primary outcome measure)